Go Pro
→ Major Buy Alert Issued for October 31st (From TradeSmith) (Ad)tc pixel Free AGY Stock Alerts

Allergy Therapeutics (AGY) Competitors

Allergy Therapeutics logo
GBX 5 +0.24 (+5.04%)
As of 07:50 AM Eastern
Compare

AGY vs. VEC, ERGO, BMY, AMYT, and APH

Should you buy Allergy Therapeutics stock or one of its competitors? Allergy Therapeutics's main competitors and comparable companies include Vectura Group (VEC), Ergomed (ERGO), Bloomsbury Publishing (BMY), Amryt Pharma (AMYT), and Alliance Pharma (APH). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Allergy Therapeutics compare to Vectura Group?

Vectura Group (LON:VEC) and Allergy Therapeutics (LON:AGY) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, valuation, earnings, media sentiment, institutional ownership and profitability.

0.0% of Allergy Therapeutics shares are held by institutional investors. 3.6% of Allergy Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Vectura Group has a net margin of 0.00% compared to Allergy Therapeutics' net margin of -85.46%. Allergy Therapeutics' return on equity of 409.00% beat Vectura Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Vectura GroupN/A N/A N/A
Allergy Therapeutics -85.46%409.00%-34.76%

Vectura Group has higher revenue and earnings than Allergy Therapeutics. Allergy Therapeutics is trading at a lower price-to-earnings ratio than Vectura Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vectura Group£190.60M0.00N/A£20.10N/A
Allergy Therapeutics£57.29M5.53-£52.59M-£0.97N/A

In the previous week, Vectura Group's average media sentiment score of 0.00 equaled Allergy Therapeutics'average media sentiment score.

Company Overall Sentiment
Vectura Group Neutral
Allergy Therapeutics Neutral

Summary

Vectura Group beats Allergy Therapeutics on 5 of the 8 factors compared between the two stocks.

How does Allergy Therapeutics compare to Ergomed?

Allergy Therapeutics (LON:AGY) and Ergomed (LON:ERGO) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, dividends, institutional ownership, earnings, valuation and analyst recommendations.

In the previous week, Allergy Therapeutics' average media sentiment score of 0.00 equaled Ergomed'saverage media sentiment score.

Company Overall Sentiment
Allergy Therapeutics Neutral
Ergomed Neutral

0.0% of Allergy Therapeutics shares are owned by institutional investors. Comparatively, 71.1% of Ergomed shares are owned by institutional investors. 3.6% of Allergy Therapeutics shares are owned by company insiders. Comparatively, 18.2% of Ergomed shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Ergomed has a net margin of 9.87% compared to Allergy Therapeutics' net margin of -85.46%. Allergy Therapeutics' return on equity of 409.00% beat Ergomed's return on equity.

Company Net Margins Return on Equity Return on Assets
Allergy Therapeutics-85.46% 409.00% -34.76%
Ergomed 9.87%18.08%10.16%

Ergomed has higher revenue and earnings than Allergy Therapeutics. Allergy Therapeutics is trading at a lower price-to-earnings ratio than Ergomed, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Allergy Therapeutics£57.29M5.53-£52.59M-£0.97N/A
Ergomed£152.09M0.00£15M£0.29N/A

Allergy Therapeutics has a beta of 0.835, meaning that its share price is 17% less volatile than the broader market. Comparatively, Ergomed has a beta of 0.79, meaning that its share price is 21% less volatile than the broader market.

Summary

Ergomed beats Allergy Therapeutics on 8 of the 10 factors compared between the two stocks.

How does Allergy Therapeutics compare to Bloomsbury Publishing?

Bloomsbury Publishing (LON:BMY) and Allergy Therapeutics (LON:AGY) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk, media sentiment and dividends.

42.2% of Bloomsbury Publishing shares are held by institutional investors. Comparatively, 0.0% of Allergy Therapeutics shares are held by institutional investors. 3.6% of Bloomsbury Publishing shares are held by insiders. Comparatively, 3.6% of Allergy Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Bloomsbury Publishing has a net margin of 8.28% compared to Allergy Therapeutics' net margin of -85.46%. Allergy Therapeutics' return on equity of 409.00% beat Bloomsbury Publishing's return on equity.

Company Net Margins Return on Equity Return on Assets
Bloomsbury Publishing8.28% 12.74% 7.82%
Allergy Therapeutics -85.46%409.00%-34.76%

Bloomsbury Publishing has higher revenue and earnings than Allergy Therapeutics. Allergy Therapeutics is trading at a lower price-to-earnings ratio than Bloomsbury Publishing, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bloomsbury Publishing£325.90M1.58£37.37M£32.8019.42
Allergy Therapeutics£57.29M5.53-£52.59M-£0.97N/A

Bloomsbury Publishing has a beta of 0.418, suggesting that its stock price is 58% less volatile than the broader market. Comparatively, Allergy Therapeutics has a beta of 0.835, suggesting that its stock price is 17% less volatile than the broader market.

In the previous week, Bloomsbury Publishing had 1 more articles in the media than Allergy Therapeutics. MarketBeat recorded 1 mentions for Bloomsbury Publishing and 0 mentions for Allergy Therapeutics. Bloomsbury Publishing's average media sentiment score of 0.00 equaled Allergy Therapeutics'average media sentiment score.

Company Overall Sentiment
Bloomsbury Publishing Neutral
Allergy Therapeutics Neutral

Bloomsbury Publishing currently has a consensus price target of GBX 792.50, indicating a potential upside of 24.41%. Given Bloomsbury Publishing's stronger consensus rating and higher probable upside, research analysts plainly believe Bloomsbury Publishing is more favorable than Allergy Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bloomsbury Publishing
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Allergy Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

Bloomsbury Publishing beats Allergy Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Allergy Therapeutics compare to Amryt Pharma?

Amryt Pharma (LON:AMYT) and Allergy Therapeutics (LON:AGY) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, dividends, valuation, earnings, profitability and analyst recommendations.

Amryt Pharma has a net margin of 0.00% compared to Allergy Therapeutics' net margin of -85.46%. Allergy Therapeutics' return on equity of 409.00% beat Amryt Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Amryt PharmaN/A N/A N/A
Allergy Therapeutics -85.46%409.00%-34.76%

In the previous week, Amryt Pharma's average media sentiment score of 0.00 equaled Allergy Therapeutics'average media sentiment score.

Company Overall Sentiment
Amryt Pharma Neutral
Allergy Therapeutics Neutral

Amryt Pharma has higher revenue and earnings than Allergy Therapeutics. Allergy Therapeutics is trading at a lower price-to-earnings ratio than Amryt Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amryt Pharma£210.24M0.00N/A-£33.00N/A
Allergy Therapeutics£57.29M5.53-£52.59M-£0.97N/A

0.0% of Allergy Therapeutics shares are held by institutional investors. 3.6% of Allergy Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Amryt Pharma and Allergy Therapeutics tied by winning 4 of the 8 factors compared between the two stocks.

How does Allergy Therapeutics compare to Alliance Pharma?

Allergy Therapeutics (LON:AGY) and Alliance Pharma (LON:APH) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, dividends, risk, institutional ownership, analyst recommendations, media sentiment, earnings and profitability.

Alliance Pharma has higher revenue and earnings than Allergy Therapeutics. Alliance Pharma is trading at a lower price-to-earnings ratio than Allergy Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Allergy Therapeutics£57.29M5.53-£52.59M-£0.97N/A
Alliance Pharma£183.50M1.91-£33.65M-£6.20N/A

Alliance Pharma has a net margin of -6.00% compared to Allergy Therapeutics' net margin of -85.46%. Allergy Therapeutics' return on equity of 409.00% beat Alliance Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Allergy Therapeutics-85.46% 409.00% -34.76%
Alliance Pharma -6.00%-5.04%5.98%

0.0% of Allergy Therapeutics shares are held by institutional investors. Comparatively, 66.3% of Alliance Pharma shares are held by institutional investors. 3.6% of Allergy Therapeutics shares are held by insiders. Comparatively, 12.0% of Alliance Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Allergy Therapeutics' average media sentiment score of 0.00 equaled Alliance Pharma'saverage media sentiment score.

Company Overall Sentiment
Allergy Therapeutics Neutral
Alliance Pharma Neutral

Allergy Therapeutics has a beta of 0.835, meaning that its share price is 17% less volatile than the broader market. Comparatively, Alliance Pharma has a beta of 0.67, meaning that its share price is 33% less volatile than the broader market.

Summary

Alliance Pharma beats Allergy Therapeutics on 6 of the 11 factors compared between the two stocks.

Get Allergy Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for AGY and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AGY vs. The Competition

Export
MetricAllergy TherapeuticsPharmaceuticals IndustryHealthcare SectorLON Exchange
Market Cap£316.63M£12.22B£7.11B£2.80B
Dividend Yield8.33%2.63%2.53%6.18%
P/E Ratio-5.15797.14274.42366.17
Price / Sales5.53751.87600.7289,425.29
Price / Cash3.6681.7977.3827.89
Price / Book50.6710.4710.926.83
Net Income-£52.59M£2.83B£3.50B£5.89B
7 Day PerformanceN/A-1.64%-2.07%-0.75%
1 Month Performance-7.75%-5.80%-6.32%16.84%
1 Year Performance-41.18%-3.84%8.92%16.40%

Allergy Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AGY
Allergy Therapeutics
N/AGBX 5
+5.0%		N/A-43.7%£316.63M£57.29MN/A612
VEC
Vectura Group
N/AN/AN/AN/A£1.01B£190.60M8.209,200
ERGO
Ergomed
N/AN/AN/AN/A£701.00M£152.09M4,641.386
BMY
Bloomsbury Publishing
2.4169 of 5 stars		GBX 624
+1.1%		GBX 792.50
+27.0%		+33.3%£504.46M£325.90M19.0234,300
AMYT
Amryt Pharma
N/AN/AN/AN/A£457.11M£210.24MN/A290

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:AGY) was last updated on 10/2/2026 by MarketBeat.com Staff.
From Our Partners
Elon Warns "America Will Go Bankrupt". Trump's Plan Inside.
National debt just crossed 40 trillion dollars, and Elon Musk says America is 1,000% going to go bankrupt with...
American Hartford Gold | Sponsoredtc pixel
MILLIONAIRE MASTERCLASS INVITE: Altucher
James Altucher says Elon Musk is preparing an unprecedented project set to surface on December 8th. Altuche...
Paradigm Press | Sponsoredtc pixel
The investigation Porter spent tens of thousands to document
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...
Porter & Company | Sponsoredtc pixel
A new kind of civil war is coming after election day?
Across America, AI-driven backlash is fueling protests, lawsuits, and moratoria that could reshape the politic...
Stansberry Research | Sponsoredtc pixel
How Elon’s Empire Ends (and how to profit)
Marc Chaikin, the 60 year Wall Street veteran whose Chaikin Money Flow indicator sits on every Bloomberg termi...
Chaikin Analytics | Sponsoredtc pixel
How options let you do more with less capital
Would you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...
Base Camp Trading | Sponsoredtc pixel
My next big call (under $1)
Crypto traders have a name for this month... Uptober. Since 2013, Bitcoin has closed October higher in 10 of 1...
Crypto 101 Media | Sponsoredtc pixel
Major Buy Alert Issued for October 31st
Keith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...
TradeSmith | Sponsoredtc pixel